Healios

4593.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2025-12

Revenue¥104m-81.4% YoY Operating income−¥3.3bn—Net income (owners)−¥2.2bn—Total assets¥17.1bn+20.2% YoY EPS (basic)¥-20.59+57.0% YoY

Full financial history and reports →

Stock price4593 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Aug 12 · JST1 filing

15:33MATERIALHealios · Event with a material impact on financial position

Mon, Jul 6 · JST1 filing

10:295% STAKEHealios · Morgan Stanley & Co. International plc + 1 joint holder · 6.99% → 3.36%−3.63pp

Thu, May 14 · JST1 filing

15:32MATERIALHealios · Event with a material impact on financial position

Thu, Feb 19 · JST1 filing

16:175% STAKEHealios · Athos Capital Limited · 20.75% → 30.52%+9.77pp

Mon, Feb 16 · JST1 filing

15:34MATERIALHealios · Event with a material impact on financial position

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
Athos Capital Limited	30.52%	+9.68pp	2026-02-19
Tadahisa Kagimoto	28.19%	-0.01pp	2025-10-09
Morgan Stanley & Co. International plc	7.15%	+0.01pp	2026-08-06

Each holder's own ratio from its most recent large-shareholding report.